menu
    • menu
    [{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Servier"},{"orgOrder":0,"company":"XBiotech","sponsor":"The French National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"Tipiracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ The French National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"XBiotech \/ The French National Cancer Institute"},{"orgOrder":0,"company":"Cancer Research","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Tipiracil HCl","moa":"||Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cancer Research \/ UCB Pharma S.A","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research \/ UCB Pharma S.A"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||CXCR-5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Trifluridine

    Menu

    Trifluridine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CytoDyn

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            CytoDyn

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leronlimab,Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoDyn Completes FDA Meeting on Leronlimab for Relapsed Colorectal Cancer Study

                            Details : PRO-140 (leronlimab) a monocloncal antibody works by blocking the activity of CCR5 receptor, being developed in combination with trifluridine plus tipiracil and bevacizumab for CCR5+, MSS mCRC.

                            Product Name : Vyrologix

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 08, 2024

                            Lead Product(s) : Leronlimab,Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Delcath Systems

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Hydrochloride,Tipiracil Hydrochloride,Trifluridine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delcath Gets FDA IND Clearance for Phase 2 Trial Of HEPZATO™ in Liver Cancer

                            Details : Hepzato kit is a drug/device product which administers melphalan directly to the liver through the HDS, being investigated in combination with trifluridine-tipiracil for metastatic colorectal cancer.

                            Product Name : Hepzato

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Melphalan Hydrochloride,Tipiracil Hydrochloride,Trifluridine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cancer Research

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UCB6114,Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cancer Research UK Signs Multi-Project Collaboration With UCB To Advance Oncology Antibody Candidates

                            Details : The collaboration focuses on the development of two antibody candidates, UCB6114 and UCB4594 by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB’s renowned antibody disco...

                            Product Name : UCB6114

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 03, 2023

                            Lead Product(s) : UCB6114,Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taiho Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. Food and Drug Administration Accepts for Priority Review Taiho Oncology's Supplemental New Drug Applicati...

                            Details : Lonsurf consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, it has demonstrated anti-tumor activity against refractory colorectal cancer, in combination with bevacizumab.

                            Product Name : Lonsurf

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Taiho Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metast...

                            Details : Lonsurf (trifluridine/tipiracil), an oral nucleoside antitumor agent, got approved as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC).

                            Product Name : Lonsurf

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 08, 2023

                            Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Servier

                            France arrow
                            German Wound Congress
                            Not Confirmed

                            Servier

                            France arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Taiho Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (Lonsurf®) In Combination...

                            Details : Lonsurf is an oral nucleoside antitumor agent which consists trifluridine, and tipiracil (TP inhibitor), which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine results in DNA dysfunction and inhibition of cell proliferatio...

                            Product Name : Lonsurf

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Taiho Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Servier

                            France arrow
                            German Wound Congress
                            Not Confirmed

                            Servier

                            France arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Taiho Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Met...

                            Details : Lonsurf (trifluridine) and tipiracil consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP.

                            Product Name : Lonsurf

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 09, 2022

                            Lead Product(s) : Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Taiho Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            XBiotech

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vilamakitug,Trifluridine,Tipiracil Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : The French National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Supp...

                            Details : Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer in subjects that have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine.

                            Product Name : Natrunix

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 28, 2022

                            Lead Product(s) : Vilamakitug,Trifluridine,Tipiracil Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : The French National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Taiho Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Servier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Taiho Oncology and Servier To Present Data on LONSURF®at 2021 ASCO Gastrointestinal Cancers Symposium

                            Details : Data for LONSURF® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer and metastatic gastroesophageal junction adenocarcinoma will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal...

                            Product Name : Lonsurf

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 01, 2021

                            Lead Product(s) : Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Servier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Natco Pharma

                            India arrow
                            German Wound Congress
                            Not Confirmed

                            Natco Pharma

                            India arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natco Pharma Launches Tipanat Tabs in India to Treat Advanced Colorectal and Gastric Cancer

                            Details : Natco Pharma launched novel fixed-dose combination of Trifluridine+Tipiracil under the brand name Tipanat, is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.

                            Product Name : Tipanat

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 18, 2021

                            Lead Product(s) : Trifluridine,Tipiracil HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth